Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Alembic Pharma's...

    Alembic Pharma's partner launches drug for depressive disorder

    Written by supriya kashyap kashyap Published On 2017-03-05T10:43:12+05:30  |  Updated On 5 March 2017 10:43 AM IST

    New Delhi : Drug firm Alembic Pharmaceuticals said its partner Breckenridge Pharma has launched desvenlafaxine succinate extended release tablets used in treatment of major depressive disorder.


    Alembic Pharma had received approval of its ANDA of desvenlafaxine succinate extended release tablets of strengths 50 mg and 100 mg in June 2015.


    These are therapeutically equivalent to Pristiq of Pfizer.


    "The ANDA was filed as a Paragraph IV on the first-to file date and will share 180 day exclusivity with other ANDA first fillers," Alembic Pharma said in a regulatory filing.


    "The paragraph IV litigation was settled on terms that are confidential," it added.


    Alembic further said it is the manufacturer of ANDA which will be marketed by Breckenridge.


    Desvenlafaxine is a prescription drug used in the treatment of major depressive disorder, and is in the class of medications called selective serotonin and neropinephrine reuptake inhibitors, it added.


    Shares of Alembic were trading at Rs 603.10, up 1.06 per cent from the previous close on BSE.

    Abbreviated New Drug ApplicationAlembicANDAdepressive disorderDesvenlafaxine Succinatemajor depressive disordersPfizer
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok